The highly conserved Epidermal Growth Factor-receptor (Egfr) pathway is required in all animals for normal development and homeostasis; consequently, aberrant Egfr signaling is implicated in a number of diseases. Genetic analysis of Drosophila melanogaster Egfr has contributed significantly to understanding this conserved pathway and led to the discovery of new components and targets. Here we used microarray analysis of third instar wing discs, in which Egfr signaling was perturbed, to identify new Egfr-responsive genes. Upregulated transcripts included five known targets suggesting the approach was valid. We investigated the function of 29 previously uncharacterized genes, which had pronounced responses. The Egfr pathway is important for wing-vein patterning and using reverse genetic analysis we identified five genes that showed venation defects. Three of these genes are expressed in vein primordia and all showed transcriptional changes in response to altered Egfr activity consistent with being targets of the pathway. Genetic interactions with Egfr further linked two of the genes, Sulfated 
INTRODUCTION
The EGF receptor (Egfr) pathway is required for cell proliferation, differentiation, migration, and survival during development (reviewed for Drosophila in (SHILO 2005) ).
Drosophila Egfr is activated by four ligands; three in the TGF-α family-spitz (spi), gurken (grk) and keren (krn) and a neuregulin called vein (vn) . The pathway is controlled by multiple regulatory mechanisms that can either dampen or amplify the signal. Components of these regulatory mechanisms include transcriptional targets of the signaling pathway and thus serve as negative and positive feedback loops (reviewed in (AVRAHAM and YARDEN 2011) ). Negative feedback regulators include argos (aos) KLEIN et al. 2004; SCHWEITZER et al. 1995) , sprouty (sty) (CASCI et al. 1999) , kekkon-1 (GHIGLIONE et al. 1999) , MAPK Phosphatase 3 (Mkp3) (GOMEZ et al. 2005; KIM et al. 2003) , mae (VIVEKANAND et al. 2004 ) and d-Cbl (PAI et al. 2000) . Positive feedback regulators include the two Egfr activating ligands, vn (GOLEMBO et al. 1999; WANG et al. 2000; WASSERMAN and FREEMAN 1998; WESSELLS et al. 1999) and spi (WASSERMAN and FREEMAN 1998) , pointed (pnt) (GABAY et al. 1996 ) and a miRNA, miR7, which positively regulates the pathway by targeting the transcriptional repressor yan (LI and CARTHEW 2005) . Here we provide genetic evidence for two new feedback controls, which both function as negative regulators of Egfr signaling in the wing imaginal disc.
The Drosophila wing has proven to be a good model system to study Egfr signaling because Egfr is required for specifying the stereotypical pattern of veins separated by interveins in this tissue. A prepattern of the veins is apparent in the mature third instar imaginal disc and can be visualized, for example, by rhomboid (rho) expression (STURTEVANT et al. 1993) . Rho is required to process the TGF-α ligands to an active form and flies mutant for both rho and the neuregulin-like ligand vn lack all veins (STURTEVANT and BIER 1995; URBAN et al. 2001; URBAN et al. 2002) . In contrast to the loss of vein phenotypes seen when Egfr signaling is reduced, excessive Egfr signaling leads to extra-vein phenotypes. In the third instar wing disc, vn is expressed along the anterior-posterior boundary in the central intervein territory, where it is required for specifying the flanking longitudinal veins (3 and 4), especially vein 4 . vn expression is induced by Hedgehog signaling (WESSELLS et al. 1999) , and indeed in addition to the Egfr pathway, the Hh, Dpp, Wingless, and Notch signaling pathways are required for positioning veins and determining their thickness (reviewed in (BLAIR 2007) ).
There have been multiple genetic screens for venation mutants leading to the discovery of new components in these signaling pathways. Screening is facilitated because the wing, like the eye, is dispensable for viability and has a stereotypical pattern that can be easily scored for changes. Here, rather than conducting another genetic screen, we employed a microarray-based approach to first identify Egfr-responsive genes. We then tested the function of candidate target genes using reverse genetics. With this approach we hoped to find novel genes that were targets of the pathway but that would not necessarily be discovered in genetic screens because they either had pleiotropic roles causing early death or only small phenotypic effects. We discovered five genes with venation defects and further genetic tests suggested that two of these, Sulfated (Sulf1) and CG4096, act as negative regulators of the Egfr pathway. The results provide more evidence for the elaborate controls that ensure precise regulation of signaling pathways. They also provide an example of genes that contribute a relatively fine control that when disrupted have only subtle effects. The work exemplifies the use of transcriptional profiling as a first line of screening, which can then be followed by reverse genetics to discover new genes in a given pathway. . Most RNAi transgenes were from the KK or GD collections at the Vienna Drosophila RNAi Center (VDRC http://stockcenter.vdrc.at/control/main). CG31048 RNAi was from the TRIP collection available at the Bloomington Drosophila Stock Center. Additional transgenes generated here are described below. GAL4-UAS crosses were carried out at 17°, 25° and 29° to provide a range of GAL4 activity levels. Trangenes for Sulf1 were generated as part of this study and also obtained from et al. 2010) . The source of a Sulf1 transgene used in a given experiment is indicated in the text. In situ hybridization: RNA probes were generated by transcription of antisense RNA with T7 RNA polymerase (Roche) from plasmid templates with cDNA inserts from the Drosophila Genomics Resource Center (DGRC; https://dgrc.cgb.indiana.edu/) or from genespecific PCR-generated templates. For PCR templates the 3' primer for each gene had a T7 recognition sequence: GAATTTAATACGACTCACTATAGG. All hybridizations were carried out using a protocol involving proteinase K treatment of the tissues (BUTLER et al. 2003) or using a method with a higher hybridization temperature that does not include this step (FIRTH and BAKER 2007) .
MATERIALS AND METHODS
Hiroshi Nakato; UAS-Sulf1, UAS-Sulf1-Golgi, UAS-Sulf1-ER (KLEINSCHMIT
Microarray Processing and
Immunohistochemistry: Late third instar wing discs were stained for dpERK with rabbit anti-dpERK antibody (Cell Signaling; (GABAY et al. 1997 )) using methods as described in Coppey et al. (COPPEY et al. 2008) . Primary antibody was used at 1:250 dilution and Cy3 conjugated goat anti-rabbit antibody (Jackson Immunoresearch) was used at 1:1000 dilution for detection. Samples were mounted in VECTASHIELD (Vector Laboratories) and imaged using a Nikon C90i confocal microscope.
Transgenes:
We generated transgenes for ectopic expression of Sulf1 and CG6234. All transgenes were cloned into pUAST and transgenic flies were generated using standard Pelement transformation. Three or more lines were generated and examined for each gene. Sulf1:
the DGC cDNA clone SD04414 that was used to make this construct lacks the first 315 bp of coding sequence. Genomic PCR was used to generate the missing sequence, which was combined by overlapping PCR with the cDNA clone to give the full coding sequence. CG6234:
an Xho I fragment comprising the entire cDNA of the gene was excised from the DGC cDNA LP04345 clone.
RT-PCR:
S2 and S2-DER cells (SCHWEITZER et al. 1995) were treated for 7h with CuSO 4 at a final concentration of 700 µM to induce Egfr expression in the S2-DER cells.
Controls were mock treated with saline. Cells were harvested and total RNA was isolated using an RNeasy kit (Qiagen) with an in-column DNase I treatment. RNA (2 µg) from each sample was subjected to reverse transcription (RT) using an Omniscript RT kit (Qiagen). A fraction
(1/10) of the RT reaction was used as template for PCR reactions with gene-specific primers (25 cycles). Ornithine decarboxylase antizyme (Oda), which is expressed at similar levels in all cells, was used as a standard for comparison. Primers for each gene were as follows: µM to induce gene expression. The conditioned medium (7 mL) from each culture was concentrated (7 fold) using a 10 kDa cut-off spin filter (Amicon). 1 mL of this concentrate was incubated with 100 µL of agarose beads covalently linked to heparin (pre-equilibrated with dilution buffer (20 mM Tris, pH 7.2)) and incubated overnight at 4°. The beads were washed five times using low salt buffer (50 mM NaCl in dilution buffer). Bound proteins were eluted with 50 µL of high salt buffer (900 mM NaCl in dilution buffer) and samples were analyzed using
Western blotting and probing with affinity purified α-Vn antibody or α- (BUFF et al. 1998) forms of Egfr in the wing disc (Figure 1 A-E). 71B-GAL4 is expressed throughout the wing pouch, with slight down regulation at the AP and DV boundaries ( Figure 1B ). This is broader than the normal domain of Egfr signaling in the wing pouch, which is limited to a series of stripes corresponding to the future veins and wing margin, as visualized by the pattern of dpErk expression (doubly-phosphorylated Erk/MAPK; In addition to broad expression, we also chose 71B-GAL4 for this analysis because 71B-Gal4 expression is initiated at the early-late third instar. This ensures that the time between induction of the transgenes and harvesting at late-late third instar is only about 48 hours ((WESSELLS et al. 1999) ; Figure S1 A-C). The short time frame increases the likelihood that direct Egfr targets will be identified over genes that function further downstream in the gene regulatory network. These latter genes would include those that are induced or repressed once cell type reprogramming has occurred. Indeed, we found that aos, a known transcriptional target was strongly and uniformly induced ( Figure 1 Analysis of the microarray data identified a total of 162 transcripts that were expressed at significantly different levels (p≤0.05) between the Egfr ACT and Egfr DN samples. Table S1 and the primary data have been submitted to GEO (GSE34872)). Eight of these genes were also identified in other studies that conducted whole-genome transcriptional analysis of the Egfr pathway or the Ras gene, which functions downstream of Egfr (Tables 1 and 2 ; (ASHA et al. 2003; FIRTH and BAKER 2007; JORDAN et al. 2005) ). Five known target genes were also represented within the top group of 25 genes upregulated by Egfr: ventral veinless (vvl) (DE CELIS et al. 1995; LLIMARGAS and CASANOVA 1997) , sty (CASCI et al. 1999; HACOHEN et al. 1998) , pnt (GABAY et al. 1996; O'NEILL et al. 1994) , MASK (SMITH et al. 2002) and Mkp3 (GOMEZ et al. 2005; KIM et al. 2003; RINTELEN et al. 2003) . Finding differential expression of these known targets suggested that the experimental approach itself was sound and had the potential to identify novel targets.
Functional analysis of the most differentially expressed genes using reverse genetics identifies genes with roles in vein patterning: We used RNAi to test the function of 29 of the 50 most differentially expressed genes that were either poorly characterized or had unknown functions (Tables 1 and 2 ). When ubiquitously expressed using Act5C-GAL4 ( Figure S1D To further test the 29 genes for vein phenotypes, including those for which ubiquitous
RNAi was lethal, we used a number of tissue-specific GAL4 drivers to inhibit gene expression in a more restricted pattern (Table S2 ). Knockdown of CG4096 and CG4382 showed consistent extra-vein phenotypes and CG34398 showed a consistent loss of vein phenotype with a variety of GAL4 lines (Tables 3 and S2 ). An additional seven genes showed a loss of the anterior crossvein (ACV) when RNAi expression was driven with vn-GAL4 (Table S2 ). The ACV is very sensitive to Vn/Egfr signaling (CLIFFORD and SCHUPBACH 1989; SCHNEPP et al. 1996) and as vn-GAL4 is a loss-of-function allele in the vn ligand gene (CLA, unpublished observation) it may provide a sensitized genetic background for revealing genes functioning in the Egfr pathway.
These seven genes, therefore, warrant further analysis, but here we focused on the genes showing vein phenotypes that were apparent with drivers in addition to vn-GAL4.
We also tested for phenotypic effects of overexpression of CG6234 and Sulf1, using cDNA transgenes. We analyzed these genes further because in situ analysis (see below) demonstrated that both genes were expressed in vein primordia, a major target tissue for Egfr signaling in the wing disc. Ectopic expression of CG6234 with multiple drivers resulted in an extra crossvein phenotype ( Figure 2D ; Tables 3 and S2 ). Sulf1 causes a vein loss phenotype when strongly overexpressed (KLEINSCHMIT et al. 2010) . Using en-GAL4 (AZA-BLANC et al. 1997 ) to misexpress the wild-type Sulf1 transgenes we generated ( Figure 5A ), or those of Kleinschmit et al. , and growing the flies at 25° (or 29°), caused no vein-loss phenotype ((KLEINSCHMIT et al. 2010) ; Figure S2A ). However, an altered form of Sulf1 that is confined to the Golgi, did cause a strong vein-loss phenotype consistent with a role for Sulf1 in vein patterning ((KLEINSCHMIT et al. 2010) ; Figure S2C ). The Golgi-tethered form also had a stronger effect on Wingless signaling (KLEINSCHMIT et al. 2010) , which suggests that retaining the enzyme in the Golgi may enhance its function. We also found loss of the ACV when Sulf1 was misexpressed with the vn-GAL4 driver, which likely provides a sensitized background because vn-GAL4 is a mutant allele (Table   3 ; Figure 2E ). Together these data are consistent with Sulf1 acting as a negative regulator of vein development.
In situ hybridization confirms the response to Egfr signaling and identifies three genes expressed in vein primordia, an Egfr-signaling target tissue: The expression patterns of the three genes that showed venation defects with RNAi and two genes that showed venation defects following overexpression (Figure 2 ; Table 3 ) were determined in wild-type wing discs and wing discs corresponding to the genotypes examined in the microarray analysis in which Egfr signaling was altered (Table 3 ; Figure 3 ). The genes were expressed in a variety of patterns, and all showed changes in expression level or distribution, verifying the microarray data. The expression pattern and how it relates to the observed phenotypes for each of these five genes is discussed in the next sections. Figure   3A '), whereas dominant negative Egfr greatly reduced expression in the central domain where 71B-GAL4 was expressed ( Figure 3A" ). Sulf1 was also expressed robustly in S2 tissue-culture cells stably transfected with Egfr (S2-DER cells), which were induced to activate the Egfr pathway ((SCHWEITZER et al. 1995; ZAK and SHILO 1990) ; Figure S3 ). Sequence analysis also shows the presence of ETS binding sites in the Sulf1 gene that could mediate signaling through Egfr signaling ( Figure S4 ). ETS family transcription factors such as Pointed mediate Egfr/Ras/MAPK signaling (O'NEILL et al. 1994) . Induction by Egfr signaling has recently been shown to be important for the role of Sulf1 in the Hh signaling pathway (WOJCINSKI et al. 2011 ).
Sulf1: Sulf1 was expressed in all provein regions and was regulated by Egfr activity (Figure 3, A-A"). Ectopic Egfr activity promoted expression throughout the wing pouch (
RNAi of Sulf1 had no effect and amorphic mutants also have only subtle phenotypes (Table 2 ; (KLEINSCHMIT et al. 2010; YOU et al. 2011) ). Sulf1 overexpression, however, causes vein loss (Table 3 ; Figure 2E ; (KLEINSCHMIT et al. 2010) ). In further genetic tests, we showed that Sulf1 behaves functionally as a negative regulator of Egfr signaling, most likely by modulating activity of the ligand Vn (see below).
CG4096: CG4096 encodes an ADAMTS (A Disintegrin And Metalloproteinase with
ThromboSpondin motifs), a family of secreted enzymes with conserved domains conferring a variety of different functions (PORTER et al. 2005) . CG4096 is expressed in presumptive veins L3 and L4 ( Figure 3B ). Expression of CG4096 was more extensive in discs expressing Egfr ACT (Figure 3B') ; however, ectopic expression is not seen in the entire 71B-GAL4 expression domain. The specific expression of CG4096 in a subset of veins in wild type and its limited response to increased Egfr activity suggests that other factors may also be required for its expression. Also consistent with being a target of the pathway, CG4096 was expressed robustly in S2 tissue-culture cells stably transfected with Egfr (S2-DER cells), which were induced to activate the Egfr pathway ((SCHWEITZER et al. 1995; ZAK and SHILO 1990) ; Figure S3 ).
Sequence analysis also shows the presence of ETS binding sites in the CG4096 gene that could mediate signaling through Egfr signaling ( Figure S4 ).
RNAi silencing of CG4096 gave a consistent extra-vein phenotype with an additional vein fragment above longitudinal vein 2 and some vein deltas ( Figure 2C ). These phenotypes are typical of elevated Egfr signaling and seen in flies with the hypermorphic Egfr Elp allele ( Figure   4B ). The phenotype was not enhanced in flies co-expressing Dcr-2, which increases RNAi et al. 2007) . Generating a null mutant, however, will be required to determine the full loss-of-function phenotype. In further genetic tests, we showed CG4096 behaves functionally as a negative regulator of Egfr signaling most likely by modulating ligand activity (see below).
CG6234:
CG6234 is expressed in all provein regions ( Figure 3C ). Ectopic activity of Egfr elicits expression in the 71B-GAL4 pattern ( Figure 3C '), and inhibition represses expression ( Figure 3C "). CG6234 is also known to be regulated by Wg signaling (BHAMBHANI et al. 2011; FANG et al. 2006) . CG6234 encodes a protein with a predicted signal peptide, but the function of the CG6234 protein has not been elucidated (Table S3 ). Ubiquitous downregulation of CG6234
by RNAi caused lethality (Table 1) , but no venation defects were seen using more specific drivers including vn-GAL4, which is likely to provide a sensitized background for observing vein defects (Tables 3 and S2) . Overexpression of CG6234, however, caused an ectopic crossvein phenotype inducing additional ACVs and/or posterior crossveins (PCVs) ( Figure 2D ; Tables 3   and S2 ). This is distinct from that seen following widespread activation of the Egfr pathway, in which there is a more global extra-vein phenotype ( Figure 1D ). PCV with a number of drivers including vn-GAL4 (Tables 3 and S2 ; Figure 2F ). Together these data suggest that CG34398 is a transcriptional target of the Egfr pathway and plays a positive role in vein patterning.
CG4382: CG4382 encodes a glutathione S-transferase (ALIAS and CLARK 2007).
CG4382 showed robust expression in the peripodial membrane, which was strongly repressed by Egfr signaling in 71B-GAL4; UAS-Egfr ACT individuals (Figure 3 , E-E"). The peripodial membrane is a second cell layer that overlays the disc proper (columnar epithelium). 71B-GAL is expressed in the peripodial membrane ( Figure S1C ) and, therefore, there may be direct inhibition of CG4382 expression in these cells. On the other hand, activation may occur via signaling from the columnar epithelium. RNAi against CG4382 using expression with multiple different GAL4 drivers resulted in an extra-vein phenotype ( Figure 2B ; Tables 2 and S2 ). Together the data support the idea that CG4382 functions as a negative regulator of vein development, which is repressed by high Egfr signaling. The expression of CG4382 in the peripodial membrane overlying the disc proper suggests that its function in venation appears to involve communication between two cell layers, as had been noted for patterning of the major regions of the wing disc (BAENA-LOPEZ et al. 2003; PALLAVI and SHASHIDHARA 2003) . Our results suggest the peripodial membrane may also have a more specific role in vein patterning. Figure 4B) . All 29 genes were tested although not all crosses yielded viable adults. Of the nine RNAi lines that were lethal with Act5C-GAL4 (Tables 1 and 2) , we were able to examine all but two as pharate adults for gross defects and eye phenotypes (CG5800 and CG10200 died prior to this stage). From the 27 genes examined, two Based on the genetic interaction with Egfr we decided to examine Sulf1 and CG4096 in more detail.
Genetic interactions with

Genetic interaction suggests Sulf1 modulates Vn activity: vn encodes a neuregulin-like ligand
that activates Egfr in the wing . Phenotypes caused by missexpression of vn can be suppressed by co-expression of the inhibitor aos (WESSELLS et al. 1999 ).
Misexpression of a vn transgene with en-GAL4 (en-GAL4; UAS-vn
) caused lethality mainly at the pupal stage with only 6% of animals surviving long enough to die as pharate adults with severe thoracic defects ( Figure 5B ). Remarkably, co-expression of Sulf1 rescued these individuals such that some survived to adulthood. We tested three independent lines of UAS- Figure 5C ). The rescue suggests that overexpression of Sulf1, which likely encodes a pathway inhibitor, compensated for overproduction of the ligand Vn. In order to eliminate the possibility that the rescue was non-specific and due to a dilution of GAL4 levels caused by competition for binding when an additional UAS-transgene was present, we also examined a control genotype (en-GAL4; Figure 5D ). The interaction may be limited to the ligand Vn, as we did not observe binding of sSpi to heparin ( Figure 5D ; (KLEIN et al. 2004) ).
Genetic analysis suggests CG4096 modulates Egfr signaling at the level of ligand action:
The (Table 4 ). The suppression, however, was pronounced when the dose of three ligand genes was reduced simultaneously (Table 4) 
DISCUSSION
Transcriptional profiling of Egfr signaling identified 162 genes that represent a typical genomic cross section of molecular functions:
We used a whole-genome microarray assay to detect transcripts that responded to changed activity of the Egfr pathway in the Drosophila wing disc. The GO classifications of the 130 genes for which there was information in the GO database showed a distribution of molecular functions that closely mirrors the frequencies of each category in the whole the genome (Table S1 ; Figure S4 ). This is in contrast to a large-scale gain-of-function genetic screen for genes involved in vein patterning (MOLNAR et al. 2006) , where the distribution of gene functions was biased towards recovering those encoding transcription factors and cell signaling molecules (MOLNAR et al. 2006) . The genes Molnar et al.
recovered, which included 60% of known genes in the Egfr and other major signaling, were identified based on their ability to cause a vein phenotype and this increased the recovery of control genes. Using reverse genetic analysis only 17% (5/29) of the genes we characterized as having robust transcriptional changes caused vein patterning defects (Tables 1-3) . We did, however, discover two new feedback regulators as described in a following section.
Among the remaining 32 genes with non-annotated molecular functions, 21 (65%) are predicted to encode either secreted or transmembrane proteins (Table S3 ). This exceeds the frequency of such proteins in the whole genome where genes encoding secreted proteins comprise 19% and genes encoding transmembrane proteins comprise 3.4% of the genome (http://www.pantherdb.org). BLASTP analysis indicates that 24 of the 32 genes are conserved in only in insects (17) or unique to Drosophilidae (9) ( Table S3) . We tested the function of eight of these genes using RNAi and five showed wing defects (Tables S1 and S3 ). As a group these 24
genes should be interesting to analyze because over half of those tested showed wing phenotypes, a large proportion are secreted, and they are unique to insects.
Genetic analysis of top candidates led to the discovery of two new negative feedback regulators of Egfr signaling:
We analyzed 29 Egfr-responsive genes using RNAi. This allowed us to screen rapidly through the candidates. Additional characterization identified two genes, Sulf1 and CG4096, which behave genetically as negative regulators of Egfr signaling. The potential role of these genes in the Egfr pathway is discussed next.
Sulf1 is an enzyme that modifies heparan sulfate (HS). The binding of growth factors to
HS chains attached to a protein backbone (HSPG) is important for regulating growth factor distribution, activity and interaction with other molecules, including receptors (SARRAZIN et al.
2011). HS chains are synthesized in the Golgi and then remodeled by enzymes including
sulfatases that remove specific sulfate groups. These enzymes play important roles because the final sulfation pattern is a determinant of ligand binding. Products of the Sulfated genes (Sulfs)
are endosulfatases that remove 6-O-sulfate groups from trisulfated glucosamine units (AI et al. 2006; AI et al. 2003; DHOOT et al. 2001; MORIMOTO-TOMITA et al. 2002; SHILATIFARD and CUMMINGS 1994) . There are two vertebrate genes: Sulf1 and Sulf2, and a single Drosophila gene,
Sulf1
. The genetic characterization of the mouse and Drosophila genes has confirmed the ability of the Sulf genes to act as endosulfatases by showing that Sulf loss-of-function mutants accumulate tri-sulfated disaccharides (KLEINSCHMIT et al. 2010; LAMANNA et al. 2006) .
Genetic analysis of Sulfs in vertebrates revealed that the genes have redundant biochemical functions and are not required for development, though double mutant (Sulf1 -/-; Sulf2 -/-) mice died soon after birth with low body weight caused by a defect in innervation of the esophagus (AI et al. 2007; HOLST et al. 2007; LAMANNA et al. 2006; LUM et al. 2007) . In vertebrates, the Sulfs have been linked to multiple signaling pathways, including FGF, VEGF, WNT, BMP, HH, and EGF and have also been found to be important in cancer (LAI et al. 2008; ROSEN and LEMJABBAR-ALAOUI 2010) . In Drosophila, Sulf1 mutants are adult viable and fertile, but have subtle phenotypes that demonstrate a role for the genes in Wg and Hh signaling (KLEINSCHMIT et al. 2010; WOJCINSKI et al. 2011; YOU et al. 2011) . Overexpression of Drosophila Sulf1 also suggests it has a role in FGF signaling (KAMIMURA et al. 2006 ). Here we provided the first evidence of a role for Sulf1 and HSPGs in EGF signaling in Drosophila.
We found Sulf1 is a target of Egfr signaling in the Drosophila wing. An observation also reported by Wojcinski et al. in their analysis of Sulf1 in Hh signaling (WOJCINSKI et al. 2011) .
We discovered that Sulf1 is not only induced by Egfr but also functions directly in the pathway et al. 2010) ). This genetic evidence is consistent with Sulf1 modulating Vn activity and is supported by the observation that Vn binds heparin ( Figure 5D ).
Based on these results, we hypothesize that Sulf1 reduces Vn binding to HSPGs by removal of 6-O sulfate moieties and hence effects it localization in the ECM (Figure 7 ). Some vertebrate EGF ligands are known to bind HSPGs including some neuregulins (NRGs) and heparin-binding EGF (IWAMOTO et al. 2010; MAHTOUK et al. 2006; PANKONIN et al. 2005) . The
NRGs share structural similarity with Vn because both types of growth factors have an Ig domain in addition to the EGF domain . The Ig domain in NRG is required for binding to heparin, and sulfate groups including 6-O sulfate groups play a role in the interaction (LI and LOEB 2001; PANKONIN et al. 2005) . The addition of a Drosophila EGF ligand to the collection of known ligands regulated by Sulf1 highlights the broad role HSPGs play in signaling pathways. It will be important to determine more about the Vn-HSPG interaction including discovering which proteoglycan is involved.
CG4096 contains predicted protein domains characteristic of an ADAMTS family member, including a zinc-dependent protease and three thrombospondin-like repeats ( Figure 6 ).
It is one of three genes in Drosophila belonging to the ADAMTS family ( Figure 6 ; (NICHOLSON et al. 2005) ). Only one of these, stall, has been analyzed genetically and found to be involved in ovary development (OZDOWSKI et al. 2009 ). In mammals there are 19 ADAMTS genes with diverse biological roles in the extracellular matrix (ECM) (reviewed in (APTE 2009; PORTER et al. 2005; STANTON et al. 2011) ). The genes have also been implicated in diseases including atherosclerosis, arthritis, and cancer (reviewed in (LE GOFF and CORMIER-DAIRE 2011; LIN and LIU 2010; SALTER et al. 2010; WAGSTAFF et al. 2011) ).
Sequence analysis places CG4096 closest to human ADAMTS7 and ADAMTS12 (NICHOLSON et al. 2005) . But CG4096 does not possess a protease and lacunin (PLAC) domain or a mucin domain, which are seen in mammalian genes (Figure 6; (APTE 2009; PORTER et al. 2005) . Based on domain architecture (predicted using Prodom), CG4096 most closely resembles ADAMTS1 and its sub-family of proteins ADAMTS4/5/8/15. Of these ADAMTS15 is most closely related to CG4096 by sequence ( Figure 6 ; NICHOLSON et al. 2005) .
Metalloproteases in general are well characterized for their positive roles in cancer progression through the ability to degrade the ECM and facilitate metastasis. Evidence, however, is emerging that ADAMTS proteins can also function as tumor suppressors. ADAMTS1, ADAMTS12 and ADAMTS15 act as tumor suppressors in prostate, colon and breast cancer (EL HOUR et al. 2010; MOLOKWU et al. 2010; MONCADA-PAZOS et al. 2009; PORTER et al. 2006; VILORIA et al. 2009 ). Our genetic evidence shows CG4096 has an inhibitory effect on Egfr activity. By extension to the role of Egfr/Ras in tumors this would be considered a tumor suppressor function. Interestingly, there is also a connection to the Egfr pathway in mammals where ADAMTS1 acts as an activator by promoting the shedding of heparin binding EGFligands (LIU et al. 2006; LU et al. 2009; RICCIARDELLI et al. 2011) . In contrast, and in keeping with the inhibitory function of CG4096, it has also been suggested that a self-cleaved product of ADAMTS1 could act as a repressor by sequestering ligands (LIU et al. 2006) . will be important to decipher its role in Drosophila. Any discoveries made in Drosophila are also likely to further the understanding of the ADAMTS family in other animals including humans.
New feedback controls by genes that play small roles in the Egfr signaling pathway:
The microarray screen described here allowed us to identify two secreted factors that are negative feedback regulators of the Egfr pathway. We propose that both Sulf1 and CG4096 fine tune Egfr signaling in the extracellular phase of the signaling pathway by negatively regulating the interaction between ligands and the receptor (Figure 7 ). The identification of two new negative regulators of Egfr signaling highlights the importance of mechanisms that dampen signaling. Sulf1 mutants are viable with mild morphological changes (KLEINSCHMIT et al. 2010; YOU et al. 2011) , and reducing CG4096 function with RNAi has only subtle effects. Yet these small effects on a vital appendage like a wing could have profound consequences for flies in the wild. The ability to turn off a pathway is clearly critical for development and homeostasis and as a result multiple negative regulators exist. This raises the question of how many such controls are
in place and what approaches can be used to find them. Given the genome-wide resources available for Drosophila, combining transcriptional profiling with reverse genetics is a highly tractable option that in our experience appears well suited to the discovery of genes with small effects. mechanism that may be direct or involve an additional factor (X). X could also be a ligand activator that CG4096 inhibits. 
